Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
KNSA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.03
Current: 0.01
During the past 10 years, the highest Debt-to-Equity Ratio of Kiniksa Pharmaceuticals International was 0.03. The lowest was 0.00. And the median was 0.02.
KNSA's Debt-to-Equity is ranked better than 99.88% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs KNSA: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kiniksa Pharmaceuticals International Debt-to-Equity Related Terms
Kiniksa Pharmaceuticals International Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International Debt-to-Equity Chart
KNSA vs INDV, AMRX, HIMS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International (KNSA) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kiniksa Pharmaceuticals International and its competitors. This is 50% below median its historical median of 0.02. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #1 out of 812 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Kiniksa Pharmaceuticals International's Debt-to-Equity too high?
Kiniksa Pharmaceuticals International's current Debt-to-Equity of 0.01 is 50% below median its 10-year median of 0.02. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Kiniksa Pharmaceuticals International's value of 0.01 is 96.4% below this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #1 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Debt-to-Equity compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #1 out of 812 companies for Debt-to-Equity. This places Kiniksa Pharmaceuticals International in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Kiniksa Pharmaceuticals International's value of 0.01 is 96.4% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.28, Kiniksa Pharmaceuticals International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current Debt-to-Equity of 0.01 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current Debt-to-Equity is 0.01, which is 50% below median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.26, compared to a current price of $77.80 — trading 43.4% above its estimated fair value. The current Debt-to-Equity is 0.01, which is 50% below median its 10-year median of 0.02 and 96.4% below the Drug Manufacturers industry median of 0.28. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $77.80 is trading 43.4% above its estimated GF Value™ of $54.26.
GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.
Key valuation signals for KNSA:
Debt-to-Equity: 0.01 (50% below median its 10-year median of 0.02)
GF Value™: $54.26 vs. price of $77.80 (43.4% above fair value)
Industry Position: 96.4% below the Drug Manufacturers median (#1 of 812)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score
Get the complete analysis for KNSA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
